Maravai Lifesciences Holdings, Inc. (MRVI)
NASDAQ:MRVI
MRVI Stock Chart & Stats
$2.83
$0.02(0.33%)
At close: 4:00 PM EST
$2.83
$0.02(0.33%)
Day’s Range― - ―
52-Week Range$1.67 - $4.11
Previous CloseN/A
Volume457.32K
Average Volume (3M)1.66M
Market Cap
$737.78M
Enterprise Value$607.22M
Total Cash (Recent Filing)$216.89M
Total Debt (Recent Filing)$35.58M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding146,383,160
10 Day Avg. Volume2,003,886
30 Day Avg. Volume1,659,398
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.22
Price to Sales (P/S)2.54
P/FCF Ratio-6.67
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue3.27
Enterprise Value/Gross Profit18.19
Enterprise Value/Ebitda-4.13
Forecast
1Y Price Target
$4.00Price Target Upside41.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$204.75M
Bulls Say, Bears Say
Bulls Say
Margin And ProfitabilityManagement's cost reduction efforts exceeded targets, improved gross margins and lowered fixed costs, driving a clearer path toward sustained profitability and positive cash flow.
Operational RestructuringAnalyst notes that restructuring actions improved operational stability and reorganized internal controls, strengthening the company's commercial capabilities and product pipeline.
Revenue Guidance And GrowthCompany's forward guidance implies modest growth across nucleic acid production and biologics testing, suggesting potential revenue expansion as commercial demand recovers.
Bears Say
Revenue Concentration RiskCompany remains partially reliant on revenue from COVID-related products, creating concentration risk if demand for those products weakens.
Segment VolatilityUneven performance across business segments, including a decline after removal of a one-time large order, highlights inconsistent revenue streams and raises uncertainty around future growth visibility.
Maravai Lifesciences Holdings News
MRVI FAQ
What was Maravai Lifesciences Holdings, Inc.’s price range in the past 12 months?
Maravai Lifesciences Holdings, Inc. lowest stock price was $1.67 and its highest was $4.11 in the past 12 months.
What is Maravai Lifesciences Holdings, Inc.’s market cap?
Maravai Lifesciences Holdings, Inc.’s market cap is $737.78M.
When is Maravai Lifesciences Holdings, Inc.’s upcoming earnings report date?
Maravai Lifesciences Holdings, Inc.’s upcoming earnings report date is May 11, 2026 which is in 39 days.
How were Maravai Lifesciences Holdings, Inc.’s earnings last quarter?
Maravai Lifesciences Holdings, Inc. released its earnings results on Feb 25, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.03.
Is Maravai Lifesciences Holdings, Inc. overvalued?
According to Wall Street analysts Maravai Lifesciences Holdings, Inc.’s price is currently Undervalued.
Does Maravai Lifesciences Holdings, Inc. pay dividends?
Maravai Lifesciences Holdings, Inc. does not currently pay dividends.
What is Maravai Lifesciences Holdings, Inc.’s EPS estimate?
Maravai Lifesciences Holdings, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Maravai Lifesciences Holdings, Inc. have?
Maravai Lifesciences Holdings, Inc. has 146,383,160 shares outstanding.
What happened to Maravai Lifesciences Holdings, Inc.’s price movement after its last earnings report?
Maravai Lifesciences Holdings, Inc. reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went up 9.202%.
Which hedge fund is a major shareholder of Maravai Lifesciences Holdings, Inc.?
Currently, no hedge funds are holding shares in MRVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maravai Lifesciences Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (41.34% Upside)
$4.00 (41.34% Upside)
Blogger Sentiment
Bullish
MRVI Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.03%
12-Months-Change
Fundamentals
Return on Equity
-51.07%
Trailing 12-Months
Asset Growth
-23.57%
Trailing 12-Months
Company Description
Maravai Lifesciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
MRVI Company Deck
MRVI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a clear operational turnaround: management exceeded cost-savings targets (> $65M), returned to positive adjusted EBITDA in Q4, and provided constructive 2026 guidance (revenue growth and a materially positive adjusted EBITDA outlook). Product momentum (ModTail, GMP enzymes, mRNAbuilder, IVT kits) and Cygnus' strong margins were highlighted as durable strengths. Headwinds remain, including sizable GAAP losses driven by impairment and restructuring charges, continued full-year negative adjusted EBITDA in 2025, outstanding leverage, and order lumpiness that can produce volatility. Overall, the tone is optimistic about returning to sustained profitability in 2026 while acknowledging near-term balance-sheet and GAAP earnings challenges.View all MRVI earnings summariesMRVI Revenue Breakdown
77.79% Nucleic Acid Production
22.21% Biologics Safety Testing
MRVI Stock 12 Month Forecast
Average Price Target
$4.00
▲(41.34% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---